Greenwich Biosciences Leadership

Justin Gover has served as Chief Executive Officer of GW Pharmaceuticals since January 1999, shortly after the Company was founded. He has 23 years’ experience in the pharmaceutical industry.

As Chief Executive Officer, Mr. Gover has been the lead executive responsible for the running of the company’s operations, as well as leading equity financings, strategy and business development activities. In 2001, he led the company’s initial public offering on the AIM stock exchange in London, and in 2013 led GW’s initial public offering on Nasdaq. In total, he has led equity financing rounds which have raised over $1bn.

In 2015, Mr. Gover relocated to the U.S. to open the company’s U.S. headquarters in California.

Prior to joining GW, Mr. Gover was Head of Corporate Affairs at Ethical Holdings plc, a UK-based Nasdaq listed company, where he was responsible for the company’s strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations.

Mr. Gover serves on the Board of Directors of the Biotechnology Innovation Organization (BIO). He holds an M.B.A. from the INSEAD business school in France and a BSc (Hons) from Bristol University.

Angelique Lee Rowley is an US General Counsel and Compliance Officer at GREENWICH BIOSCIENCES INC; VP, Global Chief Compliance Officer; R&D Legal Lead at GREENWICH BIOSCIENCES INC; and Probate Lawyer at Pro Bono Partnership Inc. and is based in Carlsbad, California. She has worked as Director, Integration; Legal & Compliance liaison at Siemens Healthcare Diagnostics; Director Of Compliance at Siemens Healthineers; and Marketing Analyst, Translator at Mari Hispanic Field Services. Angelique studied at Loyola Law School between 2003 and 2007 and Chapman University between 1995 and 2000.

Justin Gover has served as Chief Executive Officer of GW Pharmaceuticals since January 1999, shortly after the Company was founded. He has 23 years’ experience in the pharmaceutical industry.

As Chief Executive Officer, Mr. Gover has been the lead executive responsible for the running of the company’s operations, as well as leading equity financings, strategy and business development activities. In 2001, he led the company’s initial public offering on the AIM stock exchange in London, and in 2013 led GW’s initial public offering on Nasdaq. In total, he has led equity financing rounds which have raised over $1bn.

In 2015, Mr. Gover relocated to the U.S. to open the company’s U.S. headquarters in California.

Prior to joining GW, Mr. Gover was Head of Corporate Affairs at Ethical Holdings plc, a UK-based Nasdaq listed company, where he was responsible for the company’s strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations.

Mr. Gover serves on the Board of Directors of the Biotechnology Innovation Organization (BIO). He holds an M.B.A. from the INSEAD business school in France and a BSc (Hons) from Bristol University.

Justin Gover has served as Chief Executive Officer of GW Pharmaceuticals since January 1999, shortly after the Company was founded. He has 23 years’ experience in the pharmaceutical industry.

As Chief Executive Officer, Mr. Gover has been the lead executive responsible for the running of the company’s operations, as well as leading equity financings, strategy and business development activities. In 2001, he led the company’s initial public offering on the AIM stock exchange in London, and in 2013 led GW’s initial public offering on Nasdaq. In total, he has led equity financing rounds which have raised over $1bn.

In 2015, Mr. Gover relocated to the U.S. to open the company’s U.S. headquarters in California.

Prior to joining GW, Mr. Gover was Head of Corporate Affairs at Ethical Holdings plc, a UK-based Nasdaq listed company, where he was responsible for the company’s strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations.

Mr. Gover serves on the Board of Directors of the Biotechnology Innovation Organization (BIO). He holds an M.B.A. from the INSEAD business school in France and a BSc (Hons) from Bristol University.